Zhejiang Starry Pharm Co Ltd Total Liabilities
Zhejiang Starry Pharm Co Ltd total liabilities. Based on the latest financial reports, Zhejiang Starry Pharm Co Ltd (603520) has total liabilities worth CN¥3.69 Billion CNY (≈ $540.43 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Zhejiang Starry Pharm Co Ltd asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Zhejiang Starry Pharm Co Ltd (2011–2025)
Total liabilities of Zhejiang Starry Pharm Co Ltd from 2011 to 2025. This chart illustrates how Zhejiang Starry Pharm Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore Zhejiang Starry Pharm Co Ltd long-term investment intensity to see how much of total assets are deployed in long-term investments.
Zhejiang Starry Pharm Co Ltd Competitors by Total Liabilities
The table below lists competitors of Zhejiang Starry Pharm Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Guangdong Green Precision Components Co. Ltd.
SHE:300968
|
China | CN¥399.05 Million |
|
HCM II Acquisition Corp. Unit
NASDAQ:HONDU
|
USA | $15.00 Million |
|
Shenzhen Prince New Materials Co Ltd
SHE:002735
|
China | CN¥1.49 Billion |
|
Jiangsu Yike Food Group Co.Ltd
SHE:301116
|
China | CN¥3.57 Billion |
|
Inox Green Energy Services Limited
NSE:INOXGREEN
|
India | Rs3.98 Billion |
|
Tibet Weixinkang Medicine Co Ltd
SHG:603676
|
China | CN¥423.85 Million |
|
Shenzhen Soling Industrial Co Ltd
SHE:002766
|
China | CN¥187.91 Million |
|
Assure Tech Hangzhou Co Ltd
SHG:688075
|
China | CN¥611.60 Million |
Liability Composition Analysis (2011–2025)
This chart breaks down Zhejiang Starry Pharm Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 603520 current and non-current assets.
Liquidity & Leverage Metrics
Zhejiang Starry Pharm Co Ltd Total Liabilities Ratios Explained
Zhejiang Starry Pharm Co Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.02 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.43 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.59 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Zhejiang Starry Pharm Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Zhejiang Starry Pharm Co Ltd (2011–2025)
The table below shows the annual total liabilities of Zhejiang Starry Pharm Co Ltd from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥3.59 Billion ≈ $525.48 Million |
+5.27% |
| 2024-12-31 | CN¥3.41 Billion ≈ $499.16 Million |
-9.22% |
| 2023-12-31 | CN¥3.76 Billion ≈ $549.84 Million |
+6.42% |
| 2022-12-31 | CN¥3.53 Billion ≈ $516.69 Million |
+31.71% |
| 2021-12-31 | CN¥2.68 Billion ≈ $392.29 Million |
+5.48% |
| 2020-12-31 | CN¥2.54 Billion ≈ $371.92 Million |
+3.48% |
| 2019-12-31 | CN¥2.46 Billion ≈ $359.41 Million |
+14.57% |
| 2018-12-31 | CN¥2.14 Billion ≈ $313.71 Million |
+87.90% |
| 2017-12-31 | CN¥1.14 Billion ≈ $166.95 Million |
+6.98% |
| 2016-12-31 | CN¥1.07 Billion ≈ $156.06 Million |
+4.50% |
| 2015-12-31 | CN¥1.02 Billion ≈ $149.35 Million |
+42.08% |
| 2014-12-31 | CN¥718.34 Million ≈ $105.12 Million |
+15.34% |
| 2013-12-31 | CN¥622.78 Million ≈ $91.13 Million |
+27.47% |
| 2012-12-31 | CN¥488.57 Million ≈ $71.49 Million |
+15.70% |
| 2011-12-31 | CN¥422.27 Million ≈ $61.79 Million |
-- |
About Zhejiang Starry Pharm Co Ltd
Zhejiang Starry Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical raw materials in China and internationally. It operates through Contrast Agent Series, Quinolone Series, CMO/CDMO, and Others segments. The company offers preparation products comprising iohexol, iopamidol, iodixanol, iomeprol, ioversol, and gadoben… Read more